In the meantime, negotiations started a few months ago thanks to the support of the Italian-Russian Chamber of Commerce, which will allow the relocation and production of the Sputnik V vaccine in Europe.
In the past few hours, CEO Kirill Dmitriev of the Russian Direct Investment Fund (RDIF) confirmed that he has reached an agreement with the company ADIENNE Pharma & Biotech for the production of Sputnik V in Italy, signing the first European contract for the local production of the vaccine, as reported by the Italian-Russian Chamber of Commerce (CCIR.it).
The partnership will allow production to start as early as July 2021. The innovative production process will help create new jobs and will allow Italy to control the entire production process of the preparation. This will allow the production of 10 million doses by the end of the year.
Russian authorities are working on over 20 collaborative projects in Europe and the Sputnik V vaccine has already been registered in over 45 countries around the world.
The agreement between Russia and the associated company is the first agreement with a European partner. This is a historic agreement that shows the state of health of relations between the two countries and underlines how Italian companies know how to see beyond political controversies.
The President of the Italian-Russian Chamber of Commerce, Vincenzo Trani, confirmed that “Italian companies are strategic, have unique skills and competences in the European panorama, and are able to face the market with flexibility and speed.
“I am sure that this collaboration will allow new investments in the pharmaceutical sector in Italy with positive effects in terms of employment for the benefit of the entire industry.
“At this moment, the creation of a vaccine that is safe and available for all is essential to get the companies and economies of our countries out of this situation of instability for public health. We have made a ‘relay’ without shirts or political flags.”
The Sputnik V vaccine in recent weeks has begun the review process by European authorities that will allow the administration to citizens.
Ang background
This partnership comes after many months of dialogue thanks also to the invaluable support of the Italian Embassy in Moscow. The CCIR has always promoted Made with Italy, in this case being a mixed chamber of commerce promoting Made with Russia.
The Italian-Russian Chamber of Commerce (CCIR) will contribute to the development of economic, technical, legal, scientific, and cultural collaboration between Italy and the Russian Federation as early as October 2020 with the support of the Italian Embassy in Moscow through promoted meetings between Italian and European companies with Russian institutional counterparts to verify the opportunities in terms of cooperation relating to the production of the Russian Sputnik V vaccine in Italy.
The meetings, promoted by the Italian-Russian Chamber of Commerce, are aimed at identifying strategic partners in Italy to prepare the production of the Sputnik V vaccine in the Italian territory by using the Italian knowledge and excellence of the Italian drug industry to face the growing demand for doses of vaccine preparations.
In particular, in the last months of 2020, the Italian associated company Adienne Srl, part of the multinational ADIENNE Pharma & Biotech founded and chaired by Antonio Francesco Di Naro, with the support of the Italian-Russian Chamber of Commerce, has promoted a strategic agreement for the production of the Russian anti-COVID Sputnik V.
